Diane C. Bodurka

The University of Texas MD Anderson Cancer Center

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Charlotte C. Sun

The University of Texas MD Anderson Cancer Center

120

Lois M. Ramondetta

The University of Texas MD Anderson Cancer Center

Karen H. Lu

The University of Texas MD Anderson Cancer Center

Michael Frumovitz

The University of Texas MD Anderson Cancer Center

David M. Gershenson

The University of Texas MD Anderson Cancer Center

Pamela T. Soliman

The University of Texas MD Anderson Cancer Center

Shannon N. Westin

The University of Texas MD Anderson Cancer Center

Kathleen M. Schmeler

The University of Texas MD Anderson Cancer Center

Larissa A. Meyer

The University of Texas MD Anderson Cancer Center

Robert L. Coleman

Texas Oncology

Cooperative Institutions

The University of Texas MD Anderson Cancer Center

510

Gynecologic Oncology Group

101

The University of Texas Health Science Center at Houston

Memorial Sloan Kettering Cancer Center

Baylor College of Medicine

Dana-Farber Cancer Institute

Massachusetts General Hospital

Harvard University

Cornell University

Johns Hopkins University

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Phase II trial of capecitabine in recurrent squamous cell carcinoma of the cervix

Gynecologic Oncology (2005)

Alfred D. Jenkins Lois M. Ramondetta Charlotte C. Sun Taren Johnston Judith K. Wolf

Regimen

10.1016/j.ygyno.2005.02.029

Cite

Citations (16)

Hormonal Maintenance Therapy for Women With Low-Grade Serous Cancer of the Ovary or Peritoneum

Journal of Clinical Oncology (2017)

David M. Gershenson Diane C. Bodurka Robert L. Coleman Karen H. Lu Anaís Malpica

Purpose The purpose of this study was to examine outcomes associated with hormonal maintenance therapy (HMT) compared with routine observation (OBS) after primary cytoreductive surgery and platinum-based chemotherapy in women with stage II to IV low-grade serous carcinoma of the ovary or peritoneum. Patients and Methods Eligibility criteria for patients from our database were: treatment with primary surgery followed by platinum-based chemotherapy, stage II to IV disease, at least 2 years of follow-up for patients who had not experienced recurrence, and adequate clinical information. The two groups were compared for progression-free survival (PFS) and overall survival, and a multivariable Cox regression analysis was performed. Subset analyses for patients who were disease free or had persistent disease were also performed. Results Between 1981 and 2013, 203 eligible patients-133 who underwent OBS and 70 who received HMT-were seen at our institution. Median PFS for patients who underwent OBS was 26.4 months, compared with 64.9 months for those who received HMT ( P < .001). No statistically significant difference in overall survival was observed between the two groups (102.7 v 115.7 months, respectively). For subgroups of women who were disease free or had persistent disease, median PFS was superior for those who received HMT (81.1 v 30.0 months; P < .001 and 38.1 v 15.2 months; P < .001, respectively). Women who received HMT had a significantly lower risk of disease progression compared with those who underwent OBS (hazard ratio, 0.44; 95% CI, 0.31 to 0.64; P < .001). Conclusion Women with stage II to IV low-grade serous carcinoma who received HMT after primary treatment had significantly longer PFS compared with women who underwent OBS. These findings warrant further investigation using a prospective trial design.

Serous carcinoma

Hormonal Therapy

Progression-free survival

10.1200/jco.2016.71.0632

Cite

Citations (226)

Vacuum-assisted closure in the treatment of gynecologic oncology wound failures

Gynecologic Oncology (2004)

Veronica Schimp Cynthia A Worley Sandi Brunello Charles Levenback Judith K. Wolf

Vulvectomy

Gynecologic oncology

Negative-pressure wound therapy

10.1016/j.ygyno.2003.10.055

Cite

Citations (56)

Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers

Gynecologic Oncology (2005)

Robert L. Coleman Russell R. Broaddus Diane C. Bodurka Judith K. Wolf Thomas W. Burke

Imatinib Mesylate

Tolerability

Taxane

10.1016/j.ygyno.2005.09.041

Cite

Citations (102)

Significantly Greater Expression of ER, PR, and ECAD in Advanced-Stage Low-Grade Ovarian Serous Carcinoma as Revealed by Immunohistochemical Analysis

International Journal of Gynecological Pathology (2007)

Kwong‐Kwok Wong Karen H. Lu Anaís Malpica Diane C. Bodurka Hyun S. Shvartsman

Summary: A 2-tier system that classifies ovarian serous carcinoma (OSC) as low grade or high grade is gaining acceptance. Women with low-grade OSC generally have higher 5-year survival rates than do women with high-grade OSC. We examined the expression of various markers to further understand the molecular differences between low-grade and high-grade OSCs: the potential therapeutic targets or prognostic markers Her-2/neu, estrogen receptor, and progesterone receptor (PR); the metastasis-associated markers cyclin D1 (BCL1), E-cadherin, matrix metalloproteinase (MMP) 2, and MMP-9; and the cell proliferation-associated markers BCL1, Ki-67 antigen (Ki-67), and p53. For this immunohistochemical analysis, we used paraffin-embedded specimens from 47 patients with advanced-stage low-grade OSC and from 49 patients with advanced-stage high-grade OSC. Our results showed that low-grade tumors expressed significantly higher levels of estrogen receptor, PR, and E-cadherin than did high-grade tumors, suggesting the involvement of gonadal steroid hormones, especially in the pathogenesis of low-grade OSC; the PR positivity was also observed in the stromal component of these low-grade tumors. On the other hand, high-grade tumors trended toward increased expression of MMP-9, BCL1, p53, and Ki-67, and robust MMP-9 positivity was observed in the stromal component of these high-grade tumors. These differences may lead to the development of different therapeutic strategies for women with either the low-grade or the high-grade form of OSC.

Progesterone receptor

Serous carcinoma

10.1097/pgp.0b013e31803025cd

Cite

Citations (135)

Ovarian cancer

Cambridge University Press eBooks (2003)

Diane C. Bodurka

Ovarian cancer is the leading cause of death in women with gynecologic cancers. Often called the “Silent Killer” because there are no obvious symptoms until the disease is in its later stages, more than 23 400 new cases and 13 900 deaths were predicted from this disease in the US in 2001. One in 70 women in the US develop this disease, and 1 in 100 women die from ovarian cancer. Most women have a 1.8% lifetime risk of developing this cancer.

10.1017/cbo9780511527081.028

Cite

Citations (0)

Characteristics of Recurrence in Patients Who Underwent Lymphatic Mapping for Vulvar Cancer

The Cancer Journal (2003)

Michael Frumovitz Pedro T. Ramírez Guillermo Tortolero‐Luna Diane C. Bodurka Anaís Malpica

Frumovitz, M. MD; Ramirez, P. T. MD; Tortolero-Luna, G. MD, PhD; Bodurka, D. C. MD; Malpica, A. MD; Levenback, C. MD Author Information

Cancer recurrence

10.1097/00130404-200311000-00075

Cite

Citations (0)

Neoplastic Diseases of the Vulva